POZEN Pharmaceutical Development Company

	May 14, 2008 POZEN IND and NDA for Treximet(TM) (Sumatriptan/Naproxen Sodium) Transferred to GlaxoSmithKline

	May 08, 2008 POZEN Reports First Quarter 2008 Results

	Webcast - Replay Q1 2008 POZEN Inc. Earnings Conference Call May 8, 2008 at 11:00 AM ET

POZEN is a pharmaceutical company developing products for the treatment
of acute and chronic pain and pain-related conditions.

Baird's 2008 Growth Stock Conference
May 13, 2008

Information on Participating in a
POZEN Clinical Trial

05/14/08 12:08 p.m. ET
NASDAQ: Pozen	$14.37

Change: - 0.12	0.83%
Volume: 88,844